Abstract Library
Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.
Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.
ENETS Abstract Search
Introduction: Prolactinomas represent 50% of pituitary neuroendocrine tumours (PitNET), aggressive prolactinomas represent 15% of them.
Conference:
Presenting Author:
Authors: Asanova A, Shutova A, Pigarova E, Dzeranova L,
Keywords: prolactinoma, IHC, Pit Net, chemotherapy,
Introduction: Paragangliomas (PPGLs) are rare neuroendocrine tumors that may secrete catecholamines and their metabolites (metanephrines [MN], normetanephrine [NMN]). Secretion patterns differ by adrenal/extra-adrenal origin and genetic alteration. Catecholamines synthesis is carried by phenylalanine hydroxylase (PAH), tyrosine hydroxylase (TH), aromaticL-aminoacid decarboxylase (AADC), dopamine β-hydroxylase (DBH) and phenylethanolamine N-methyltransferase (PNMT). However, their regulation in PPGL is not entirely understood.
Conference:
Presenting Author: Tirosh A
Authors: Kaplinsky A, Halperin R, Shlomai G, Tirosh A,
Keywords: ppgl, methylation, catecholamine, pseudohypokia, metanephrine, kinase signaling, pheochromocytoma, paraganglioima,
#4089 Peptide receptor radionuclide therapy is effective for hormonal control of carcinoid syndrome
Introduction: Carcinoid syndrome (CS) is the most common functioning syndrome in neuroendocrine tumors (NET) and manifests in symptoms of flushing, diarrhea and fibrosis. Serotonin, a tryptophan metabolite, is considered the principal hormonal mediator of CS. Peptide receptor radionuclide therapy (PRRT) has established antiproliferative effects in NET, but the clinical and biochemical response to PRRT in CS patients is unknown.
Conference:
Presenting Author: Maas C
Authors: Maas C, Mulders M, Mirzaian M, van den Berg S, Brabander T,
Keywords: carcinoid syndrome, neuroendocrine tumor, peptide receptor radionuclide therapy, serotonin,
#4085 Disease-specific mortality in a single-center cohort of 427 patients with carcinoid syndrome
Introduction: The carcinoid syndrome (CS), the most prevalent hormonal syndrome in patients with a neuroendocrine tumor (NET), is associated with impaired survival. Due to the biological behaviour of NET and overall improvement in survival rates, patients with CS may not succumb to their disease. However, the contribution of NET-specific death in these patients is currently unknown.
Conference:
Presenting Author: Maas C
Authors: Maas C, Mulders M, Feelders R, de Herder W, Hofland J,
Keywords: carcinoid syndrome, neuroendocrine tumor, prognosis, survival analysis,
#3748 Association of MINEN with GIST on neurofibromatosis – A case report
Introduction: Although most digestive neuroendocrine tumors (NETs) are sporadic, around 5% of NETs occur in a context of hereditary predisposition, mainly type 1 multiple endocrine neoplasia (NEM1) and Von Hippel-Lindau disease (VHL).
Conference:
Presenting Author: